Health company Essity stated on Wednesday that it has scaled up the production of its Tork-branded hand sanitizers capacity to meet the increased demand in Europe following the challenges, impact and focus of the COVID-19 pandemic on hand hygiene.
In the Q4 2020, the company will increase its supply capacity of hand sanitizer in Europe to enable the continued high growth of the existing range. Its Professional Hygiene business, under the leading global brand Tork, has seen a steep increase in demand for hand sanitizers in response to new hygiene regulations or customers' desire to provide an additional layer of safety where water and soap are not available.
Based on the research conducted on the company's behalf in July 2020, the hand hygiene is now an integral part of everyday routines and that 74% of people now consider hand hygiene to be more a part of their overall health routine than before the COVID-19 pandemic. About 69% of respondents find hand sanitizers a good complement to washing hands.
With an increase in the sanitizer capacity, the businesses and their employees and customers can offer consistent and reliable access to hand-hygiene products when handwashing is not readily available, concluded the company.
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering